Minerva Neurosciences (NERV) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Stablecoin Development (SDEV) over the past year, gaining 50.0% versus a loss of 55.9%. Over five years, NERV leads with a -69.7% price change compared with -99.9% for SDEV. Minerva Neurosciences is the larger company by market cap ($154.7 million vs $110.7 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | SDEV |
|---|---|---|
| Share price | $3.24 | $2.14 |
| Market cap | $154.70M | $110.75M |
| 1-day change | -0.92% | -23.02% |
| YTD return | -18.66% | -90.14% |
| 1-year return | +50.00% | -55.87% |
| 5-year return | -69.72% | -99.92% |
| EPS (TTM) | $-36.12 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $99.75 |
| 52-week low | $2.24 | $0.78 |
| Distance from 52-week high | -74.00% | -97.85% |
| Analyst consensus | none | — |
| Avg. price target upside | +218.83% | — |
| Average volume | 184.44K | 11.42M |
| Shares outstanding | 47.75M | 51.75M |
| Employees | 7 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed SDEV by 105.9 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
NERV vs SDEV FAQ
Which is bigger, Minerva Neurosciences or Stablecoin Development?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $154.70M compared with $110.75M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, NERV or SDEV?
NERV returned +50.00% over the past 12 months, compared with -55.87% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.